Long-term, Interventional, Open Label Extension Study Evaluating the Safety of Tocilizumab Treatment in Patients With Polyarticular-course Juvenile Idiopathic Arthritis Who Completed the Global, Multinational Trial (WA19977) [EXTENSION OF 700049718]
Phase of Trial: Phase III
Latest Information Update: 07 Jul 2016
Price : $35 *
At a glance
- Drugs Tocilizumab (Primary)
- Indications Juvenile rheumatoid arthritis
- Focus Adverse reactions
- Sponsors Roche
- 31 Aug 2018 Biomarkers information updated
- 18 Sep 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 23 May 2013 Planned End Date changed from 1 Dec 2014 to 1 Sep 2013 as reported by ClinicalTrials.gov.